| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01316887 | A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | PHASE3 | COMPLETED | 563 | — | — | Jan 1, 2011 | Jul 21, 2012 | May 2, 2018 | 54 | United States, Chile +4 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. Medical or scientific judgment was to have been exercised in other important medical events. AEs with an onset on or after the date of the first dose of study drug and up to 1 day after the date of the last recorded dose of study drug were considered to be on-treatment AEs, Refer to the general AE/SAE module for a complete list of AEs and SAEs.
| Arm | Type | Description |
|---|---|---|
| GSK573719/GW642444 | EXPERIMENTAL | 125/25 mcg once-daily |
| GSK573719 | EXPERIMENTAL | 125 mcg once-daily |
| Placebo | PLACEBO_COMPARATOR | inactive |
| Name | Type | Description |
|---|---|---|
| 125/25 mcg once-daily GSK573719/GW642444 | DRUG | GSK573719/GW642444 |
| 125mcg once-daily GSK573719 | DRUG | GSK573719 |
| Placebo once-daily | DRUG | inactive |
Inclusion Criteria: * outpatient * signed and dated written informed consent * 40 years of age or older * male and female subjects * COPD diagnosis * at least 10 pack-year smoking history * post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 and post-albuterol/salbutamol FEV1 greater than or equal t...